Trial Profile

The Efficacy and Safety of a New Cap-dependent Endonuclease Inhibitor, TG-1000, in Adolescent and Adult Outpatients with Acute Uncomplicated Influenza: A Multicenter, Randomized, Placebo-controlled Phase III Trial

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Dec 2025 According to TaiGen Biotechnology media release, the company has officially obtained a new drug marketing authorization from the National Medical Products Administration (NMPA) of China. Its indication is for the treatment of uncomplicated influenza A and B in adults and adolescents aged 12 years and older.
31 Jul 2025 New trial record
06 Feb 2025 Status changed to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com